Drug
PF-06700841 clinical trials
Also written PF-06700841 and Brepocitinib.
- studies test it
- 25
- open now
- 2
- in phase 3
- 3
- first study started
- 2014
Keep track of what changes. Save the PF-06700841 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Other names
Combined with it in one product
Studies by the year they started
25 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 8 |
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 15
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 1
Pfizer (19) · Priovant Therapeutics, Inc. (5) · Emma Guttman (1)
Often tested with
Tested in the same studies.
PF-06651600 (4) · Zimlovisertib (1) · Ropsacitinib (1) · Itraconazole (1) · Petrolatum (1) · Suspensions (1)
Studies
Open first, then newest update. How each study uses PF-06700841 is read from its arms, and is right about nine times in ten.
Testing it · 25
- A Study of Brepocitinib in Adults With Cutaneous SarcoidosisRecruitingPhase 2/3Priovant Therapeutics, Inc.NCT06978725Written as Oral Brepocitinib
- A Phase 2/3 Study of Brepocitinib in Adults With Lichen PlanopilarisRecruitingPhase 2/3Priovant Therapeutics, Inc.NCT07532603Written as Oral Brepocitinib
- A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisCompletedPhase 3Priovant Therapeutics, Inc.NCT05437263Written as Brepocitinib
- Dual JAK1/TYK2 Inhibitor for Cicatricial AlopeciaCompletedPhase 2Emma GuttmanNCT05076006Written as PF-06700841
- A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior UveitisCompletedPhase 2Priovant Therapeutics, Inc.NCT05523765Written as Brepocitinib
- A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant DermatomyositisCompletedPhase 2Priovant Therapeutics, Inc.NCT06433999Written as Brepocitinib
- Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's DiseaseCompletedPhase 2PfizerNCT03395184Written as PF-06700841
- A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)CompletedPhase 2PfizerNCT03845517Written as PF-06700841 15 mg
- Renal Impairment Study of PF-06700841CompletedPhase 1PfizerNCT04260464Written as PF-06700841
- A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedPhase 2PfizerNCT04092452Written as PF-06700841
- Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisCompletedPhase 2PfizerNCT02958865Written as PF-06700841
- Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In PsoriasisCompletedPhase 2PfizerNCT03850483Written as PF-06700841
- A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo SubjectsCompletedPhase 2PfizerNCT03715829Written as PF06700841
- A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic ArthritisCompletedPhase 2PfizerNCT03963401Written as PF-06700841
- Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic DermatitisCompletedPhase 2PfizerNCT03903822Written as PF-06700841
- Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release FormulationsCompletedPhase 1PfizerNCT04580797Written as PF-06700841 IR
- Effect Of Multiple Dose PF-06700841 On The Pharmacokinetics Of Single Dose Oral Contraceptive SteroidsCompletedPhase 1PfizerNCT04267250Written as PF-06700841
- Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia AreataCompletedPhase 2PfizerNCT02974868Written as PF-06700841
- A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy ParticipantsCompletedPhase 1PfizerNCT04090047Written as PF-06700841
- Evaluation of Skin Irritation Potential With PF-06700841 Cream Formulation Using Negative Control in Adult Japanese Healthy ParticipantsCompletedPhase 1PfizerNCT03916250Written as PF-06700841 cream
Codes
What other systems call PF-06700841 · ClinicalTrials.gg INT001080
- MeSH (NLM) C000630838PF-06700841Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 3X8387Q25NBREPOCITINIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630838 | PF-06700841 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 3X8387Q25N | BREPOCITINIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.